15 hours ago 1

AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics

Maham Fatima

Tue, Jun 17, 2025, 1:23 AM 2 min read

AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for beginners now. In mid-May, AbbVie and ADARx Pharmaceuticals announced a collaboration and license option agreement. The partnership aims to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, such as neuroscience, immunology, and oncology.

siRNA molecules are a class of genetic medicines capable of regulating gene expression and protein production by targeting messenger RNA (mRNA) to prevent the synthesis of disease-causing proteins. This differs from traditional approaches like antibodies and small molecules, which target existing proteins. The collaboration will combine ADARx’s RNA discovery expertise and proprietary siRNA technology, which has the potential for sustained and precise mRNA silencing, with AbbVie’s extensive experience in antibody engineering, antibody drug conjugates/ADCs, and tissue delivery approaches.

AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics

A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist.

Under the terms of the agreement, ADARx will receive an upfront payment of $335 million. Additionally, ADARx is eligible to receive several billion dollars in further contingent payments, which include option-related fees and milestone payments, as well as tiered royalties on any successfully commercialized products.

AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that researches & develops, manufactures, commercializes, and sells medicines and therapies worldwide. ADARx Pharmaceuticals is a late clinical-stage biotech company that specializes in next-gen RNA therapeutics.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.